Therapeutic drug monitoring in neuropsychopharmacology: Does it hold its promises?

European Archives of Psychiatry and Clinical Neuroscience

Volumn 258, Issue SUPPL. 1, 2008, Pages 21-27

  Hiemke, Christoph ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Antidepressants; Antipsychotics; Drug drug interactions; Therapeutic drug monitoring

Indexed keywords

AMISULPRIDE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; CLOZAPINE; DOPAMINE RECEPTOR; FLUOXETINE; FLUVOXAMINE; HALOPERIDOL; MOOD STABILIZER; NEUROLEPTIC AGENT; NORTRIPTYLINE; OLANZAPINE; PAROXETINE; PERPHENAZINE; PSYCHOTROPIC AGENT; RISPERIDONE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

BIOTRANSFORMATION; BLOOD LEVEL; CLINICAL TRIAL; CONFERENCE PAPER; DRUG ABSORPTION; DRUG COST; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EXCRETION; DRUG MECHANISM; DRUG MONITORING; DRUG TRANSPORT; EATING HABIT; ENZYME METABOLISM; HUMAN; MORBIDITY; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROBLEM SOLVING; PSYCHIATRY; PSYCHOPHARMACOLOGY; SCHIZOPHRENIA; SEROTONIN UPTAKE; TARGET ORGAN;

DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; GUIDELINES AS TOPIC; HUMANS; MENTAL DISORDERS; NEUROPSYCHOLOGY; PSYCHOPHARMACOLOGY; PSYCHOTROPIC DRUGS;

EID: 41049118341     PISSN: 09401334     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00406-007-1005-y     Document Type: Conference Paper

References (58)

1. Aravagiri M, Teper Y, Marder SR (1999) Pharmacokinetics and tissue distribution of olanzapine in rats. Biopharm Drug Dispos 20:369-377
2. Åsberg M, Cronholm B, Sjöqvist F, Tuck D (1970) Correlation of subjective side effects with plasma concentrations of nortriptyline. Br Med J 4:18-21
3. Åsberg M, Cronholm B, Sjöqvist F, Tuck D (1971) Relationship between plasma level and therapeutic effect of nortriptyline. Br Med J 3:331-334
4. Baldessarini RJ, Cohen BM, Teicher MH (1998) Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Arch Gen Psychiatry 45:79-91
5. Bauer M, Whybrow PC, Angst J, Versiani M, Möller HJ (2002) World federation of societies of biological psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, Part 1: acute, continuation treatment of major depressive disorder. World J Biol Psychiatry 3:5-43
6. Baumann P, Hiemke C, Ulrich S, Eckermann G, Gaertner I, Gerlach M, Kuss HJ, Laux G, Müller-Oerlinghausen B, Rao ML, Riederer P, Zernig G (2004) The AGNP-TDM expert group consensus guidelines: Therapeutic drug monitoring in psychiatry. Pharmacopsychiatry 37:243-265
7. Bengtsson F (2004) Therapeutic drug monitoring of psychotropic drugs TDM "nouveau". Ther Drug Monit 26:145-151
8. Burke MJ, Preskorn SH (1999) Therapeutic drug monitoring of antidepressants. Cost implications and relevance to clinical practice. Clin Pharmacokinet 37:147-165
9. Correll CU, Malhotra AK, Kaushik S, McMeniman M, Kane JM (2003) Early prediction of antipsychotic response in schizophrenia. Am J Psychiatry 160:2063-2065
10. DeVane CL, Boulton DW, Miller LF, Miller RL (1999) Pharmacokinetics of trazodone and its major metabolite m-chlorophenylpiperazine in plasma and brain of rats. Int J Neuropsychopharmcol 2:17-23
11. Dolder CR, Lacro JP, Dunn LB, Jeste DV (2002) Antipsychotic medication adherence: is there a difference between typical and atypical agents? Am J Psychiatry 59:103-108
12. Farde L, Nordström AL, Wiesel F-A, Pauli S, Halldin C, Sedvall G (1992) Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry 49:538-544
13. Farde L, Wiesel FA, Halldin C, Sedvall G (1988) Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry 45:71-76
14. Gaertner I, Gaertner HJ, Vonthein R, Dietz K (2001) Therapeutic drug monitoring of clozapine in relapse prevention: a five-year prospective study. J Clin Psychopharmacol 21:305-310
15. Glotzbach RK, Preskorn SH (1982) Brain concentrations of tricyclic antidepressants: single-dose kinetics and relationship to plasma concentrations in chronically dosed rats. Psychopharmacology 78:25-27
16. 18F]desmethoxyfallypride. J Nucl Med 44:109-116
17. Gutteck U, Rentsch KM (2003) Therapeutic drug monitoring of 13 antidepressant and five neuroleptic drugs in serum with liquid chromatography-electrospray ionization mass spectrometry. Clin Chem Lab Med 41:1571-1579
18. Härtter S, Hermes B, Hiemke C (1995) Automated determination of trimipramine and N-desmethyl-trimipramine in human plasma or serum by HPLC with on-line solid phase extraction. J Liq Chromatogr 18:3495-3505
19. Härtter S, Hiemke C (1992) Column switching and high-performance liquid chromatography in the analysis of amitriptyline, nortriptyline and hydroxylated metabolites in human plasma or serum. J Chromatogr 578(2):273-282
20. Härtter S, Weigmann H, Hiemke C (2000) Automated determination of reboxetine by high-performance liquid chromatography with column-switching and ultraviolet detection. J Chromatogr B 740:135-140
21. Hiemke C, Dragicevic A, Gründer G, Härtter S, Sachse J, Vernaleken I, Müller MJ (2004) Therapeutic monitoring of new antipsychotic drugs. Ther Drug Monit 26:156-160
22. Hiemke C, Dragicevic A, Gründer G, Härtter S, Sachse J, Vernaleken I, Müller MJ (2004) Therapeutic monitoring of new antipsychotic drugs. Ther Drug Monit 26(2):156-160
23. Jaquenoud Sirot E, van der Velden JW, Rentsch K, Eap CB, Baumann P (2006) Therapeutic drug monitoring and pharmacogenetic tests as tools in pharmacovigilance. Drug Saf 29:735-768
24. Kapur S, Zipursky R, Jones C, Shammi CS, Remington G, Seeman P (2000) A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. Arch Gen Psychiatry 57:553-559
25. Kapur S, Zipursky RB, Remington G, Jones C, DaSilva J, Wilson AA et al (1998) 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation. Am J Psychiatry 155:921-928
26. Kirchherr H, Kühn-Velten WN (2006) Quantitative determination of forty-eight antidepressants and antipsychotics in human serum by HPLC tandem mass spectrometry: a multi-level, single-sample approach. J Chromatogr B 843:100-113
27. Laux G, Riederer P (1992) Plasmaspiegelbestimmung von Psychopharmaka: Therapeutisches Drug - Monitoring Versuch einer ersten Standortbestimmung. Wissenschaftliche Verlagsgesellschaft, Stuttgart
28. Leucht S, Busch R, Kissling W, Kane JM (2007) Early prediction of antipsychotic nonresponse among patients with schizophrenia. J Clin Psychiatry 68:352-360
29. Lundmark J, Bengtsson F, Nordin C, Reis M, Walinder J (2000) Therapeutic drug monitoring of selective serotonin reuptake inhibitors influences clinical dosing strategies and reduces drug costs in depressed elderly patients. Acta Psychiatr Scand 101:354-359
30. Mann K, Hiemke C, Lotz J, Schmidt LG, Lackner KJ, Bates DW (2006) Appropriateness of plasma level determinations for lithium and valproate in routine care of psychiatric inpatients with affective disorders. J Clin Psychopharmacol 26:671-673
31. Mann K, Hiemke C, Schmidt LG, Bates DW (2006) Appropriateness of therapeutic drug monitoring for antidepressants in routine psychiatric inpatient care. Ther Drug Monit 28:83-88
32. Medori R, Mannaert E, Gründer G (2006) Plasma antipsychotic concentration and receptor occupancy, with special focus on risperidone long-acting injectable. Eur Neuropsychopharmacol 16:233-240
33. Meyer JH, Wilson AA, Sagrati S, Hussey D, Carella A, Potter WZ, Ginovart N, Spencer EP, Cheok A, Houle S (2004) Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study. Am J Psychiatry 161(5):826-835
34. Müller MJ, Dragicevic A, Fric M, Gaertner I, Grasmäder K, Härtter S, Hermann E, Kuss HJ, Laux G, Oehl W, Rao ML, Rollmann N, Weigmann H, Weber-Labonte M, Hiemke C (2003) Therapeutic drug monitoring of tricyclic antidepressants: How does it work under clinical conditions. Pharmacopsychiatry 36:98-104
35. Müller MJ, Regenbogen B, Härtter S, Eich FX, Hiemke C (2007) Therapeutic drug monitoring for optimzing amisulpride therapy in patients with schizophrenia. J Psychiatr Res 41:673-679
36. Nordström A-L, Farde L, Wiesel F-A, Forslund K, Pauli S, Halldin C, Uppfeldt G (1993) Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients. Biol Psychiatry 33:227-235
37. Preskorn SH, Burke MJ, Fast GA (1993) Therapeutic drug monitoring: principles and practice. Ther Drug Monit 16:611-641
38. Preskorn SH, Fast GA (1991) Therapeutic drug monitoring for antidepressants: efficacy, safety, and cost effectiveness. J Clin Psychiatry 52(Suppl):23-33
39. Preskorn SH, Jerkovich GS (1990) Central nervous system toxicity of tricyclic antidepressants: phenomenology, course, risk factors, and role of therapeutic drug monitoring. J Clin Psychopharmacol 10:88-95
40. Rice DP (1999) The economic impact of schizophrenia. J Clin Psychiatry 60:4-6
41. Sachse J, Härtter S, Hiemke C (2005) Automated determination of ziprasidone by HPLC with column switching and spectrophotometric detection. Ther Drug Monit 27:158-162
42. Sachse J, Härtter S, Weigmann H, Hiemke C (2003) Automated determination of amisulpride by liquid chromatography with column switching and spectrophotometric detection. J Chromatogr B 784:405-410
43. Sachse J, Köller J, Härtter S, Hiemke C (2005) Automated analysis of quetiapine and other antipsychotic drugs in human blood by high performance-liquid chromatography with column-switching and spectrophotometric detection. J Chromatogr B 830:342-348
44. Simmons SA, Perry PJ, Rickert ED, Browne JL (1985) Cost-benefit analysis of prospective pharmacokinetic dosing of nortriptyline in depressed inpatients. J Affective Disord 8:47-53
45. Szegedi A, Müller MJ, Anghelescu I, Klawe C, Kohnen R, Benkert O (2003) Early improvement under mirtazapine and paroxetine predicts later stable response and remission with high sensitivity in patients with major depression. J Clin Psychiatry 64:413-420
46. Talbot PS, Laruelle M (2002) The role of in vivo molecular imaging with PET and SPECT in the elucidation of psychiatric drug action and new drug development. Eur Neuropsychopharmacol 12:503-511
47. Talvik M, Nordstrom AL, Larsen NE, Jucaite A, Cervenka S, Halldin C, Farde L (2004) A cross-validation study on the relationship between central D2 receptor occupancy and serum perphenazine concentration. Psychopharmacology (Berl) 175:148-153
48. Ulrich S, Hiemke C, Laux G, Müller-Oerlinghausen B, Havemann-Reinecke U, Riederer P, Zernig G, Baumann P (2007) Value and actuality of the prescription information for therapeutic drug monitoring of psychopharmaceuticals: A comparison with the medico-scientific evidence. Pharmacopsychiatry 40:121-127
49. Ulrich S, Läuter J (2002) Comprehensive survey of the relationship between serum concentration and therapeutic effect of amitriptyline in depression. Clin Pharmacokinet 41:853-876
50. Ulrich S, Neuhof S, Braun V, Meyer FP (1998) Therapeutic window of serum haloperidol concentration in acute schizophrenia and schizoaffective disorder. Pharmacopsychiat 31:163-169
51. Vander Zwaag C, McGee M, McEvoy JP, Freudenreich O, Wilson WH, Cooper TB (1996) Response of patients with treatment-refractory schizophrenia to clozapine within three serum level ranges. Am J Psychiatry 153:1579-1584
52. Vernaleken I, Siessmeier T, Buchholz HG, Härtter S, Hiemke C, Stoeter P, Rösch F, Bartenstein P, Gründer G (2004) High striatal occupancy of D2-like dopamine receptors by amisulpride in the brain of patients with schizophrenia. Int J Neuropsychopharmacol 7:421-430
53. Vuille F, Amey M, Baumann P (1991) Use of plasma level monitoring of antidepressants in clinical practice. Towards an analysis of clinical utility. Pharmacopsychiatry 24:190-195
54. Weigmann H, Härtter S, Hiemke C (1998) Automated determination of clomipramine and its major metabolites in human and rat serum by high-performance liquid chromatography with on-line column-switching. J Chromatogr B 710:227-233
55. Weigmann H, Härtter S, Maehrlein S, Kiefer W, Kramer G, Dannhardt G, Hiemke C (2001) Simultaneous determination of olanzapine, clozapine and demethylated metabolites in serum by on-line column-switching high-performance liquid chromatography. J Chromatogr B 759:63-71
56. Wyatt RJ, Henter I, Leary MC, Taylor E (1995) An economic evaluation of schizophrenia: 1991. Soc Psychiatr Epidemiol 30:196-205
57. 11C]raclopride. Neuropsychopharmacology 27:248-259
58. Zernig G, Lechner T, Kramer-Reinstadler K, Hinterhuber H, Hiemke C, Saria A (2004) What the clinician still has to be reminded of. Ther Drug Monit 26:582